Inotiv, Inc. provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; non-clinical toxicology and pathology services; and climate-controlled archiving services for its customers' data and samples.[ Read More ]
The intrinsic value of one NOTV stock under the base case scenario is HIDDEN Compared to the current market price of 2.68 USD, Inotiv, Inc. is HIDDEN
Current Assets | 214 M |
Cash & Short-Term Investments | 35.5 M |
Receivables | 90.4 M |
Other Current Assets | 87.9 M |
Non-Current Assets | 643 M |
Long-Term Investments | 3.68 M |
PP&E | 230 M |
Other Non-Current Assets | 409 M |
Current Liabilities | 132 M |
Accounts Payable | 32.6 M |
Short-Term Debt | 18.2 M |
Other Current Liabilities | 81.4 M |
Non-Current Liabilities | 456 M |
Long-Term Debt | 399 M |
Other Non-Current Liabilities | 56.4 M |
Revenue | 572 M |
Cost Of Revenue | 407 M |
Gross Profit | 165 M |
Operating Expenses | 247 M |
Operating Income | -81.5 M |
Other Expenses | 23.4 M |
Net Income | -105 M |
Net Income | -105 M |
Depreciation & Amortization | 54.7 M |
Capital Expenditures | -27.5 M |
Stock-Based Compensation | 7.84 M |
Change in Working Capital | 17 M |
Others | 66.5 M |
Free Cash Flow | 380 K |
Date | Value | Insider | Amount | Avg Price |
---|---|---|---|---|
5 years ago
Jun 07, 2019
|
Bought 14.9 K USD
|
Leasure Robert Jr.
President and CEO |
+ 7500
|
1.9819 USD |
11 months ago
Dec 14, 2023
|
Bought 14.1 K USD
|
Garrett Michael
Chief Commercial Officer |
+ 5000
|
2.829 USD |
11 months ago
Dec 14, 2023
|
Bought 150 K USD
|
Beattie John Gregory
Chief Operating Officer |
+ 47966
|
3.1238 USD |
1 year ago
Mar 14, 2023
|
Bought 25 K USD
|
Sagartz John E
Chief Strategy Officer |
+ 5100
|
4.91 USD |
1 year ago
Feb 22, 2023
|
Bought 35 K USD
|
Beattie John Gregory
Chief Operating Officer |
+ 5000
|
6.99 USD |
1 year ago
Dec 09, 2022
|
Sell 12.4 K USD
|
Pitchford William D
Chief Human Resources Officer |
- 2123
|
5.8246 USD |
1 year ago
Dec 01, 2022
|
Sell 6.12 K USD
|
Neff R Matthew
Director |
- 1000
|
6.12 USD |
2 years ago
Nov 01, 2022
|
Sell 10.6 K USD
|
Neff R Matthew
Director |
- 500
|
21.1201 USD |
2 years ago
Nov 01, 2022
|
Sell 10.6 K USD
|
Neff R Matthew
Director |
- 500
|
21.1261 USD |
2 years ago
Oct 17, 2022
|
Sell 19.1 K USD
|
Neff R Matthew
Director |
- 1000
|
19.1 USD |
2 years ago
Mar 15, 2022
|
Bought 76.3 K USD
|
Harkness James
Chief Operating Officer, RMS |
+ 4049
|
18.84 USD |
2 years ago
Feb 18, 2022
|
Bought 26.4 K USD
|
Davis Gregory Cole
Director |
+ 1250
|
21.12 USD |
2 years ago
Feb 18, 2022
|
Bought 59.8 K USD
|
Davis Gregory Cole
Director |
+ 2500
|
23.9255 USD |
2 years ago
Feb 17, 2022
|
Bought 25.7 K USD
|
Davis Gregory Cole
Director |
+ 1250
|
20.571 USD |
2 years ago
Feb 17, 2022
|
Bought 115 K USD
|
Leasure Robert Jr.
President and CEO |
+ 5000
|
23.0262 USD |
2 years ago
Feb 17, 2022
|
Bought 50 K USD
|
Sagartz John E
Chief Strategy Officer |
+ 2506
|
19.9516 USD |
2 years ago
Dec 22, 2021
|
Sell 132 K USD
|
Downing Philip A
Sr. VP, Preclinical Srvcs. |
- 3057
|
43.0412 USD |
3 years ago
Jun 07, 2021
|
Bought 50 K USD
|
Sagartz John E
Chief Strategy Officer |
+ 1742
|
28.7 USD |
3 years ago
May 28, 2021
|
Bought 49.9 K USD
|
Sagartz John E
Chief Strategy Officer |
+ 2012
|
24.78 USD |
3 years ago
May 27, 2021
|
Bought 120 USD
|
Sagartz John E
Chief Strategy Officer |
+ 5
|
24 USD |